Additive effects of anti-CD3 and anti-CD28 on prolongation of allogeneic skin graft survival

Transplantation

Volumn 72, Issue 11, 2001, Pages 1862-

  Yu, Xue Zhong ^a   Nitta, Yoshio ^b,c   Bidwell, Sasha J ^a   Anasetti, Claudio ^a  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD28; MONOCLONAL ANTIBODY CD3; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL MODEL; FULL THICKNESS SKIN GRAFT; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN GRAFT; T LYMPHOCYTE;

EID: 0035892779     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200112150-00030     Document Type: Letter

References (4)

1. T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs
2. Anti-CD3e F(ab′)2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens
3. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
4. CD28-specific antibody prevents graft-versus-host disease in mice